Incorporated in late 2024 in Strasbourg France, AMC Bio has a growing portfolio of diagnostics and therapeutics, including a ground-breaking Long COVID diagnostic and two preclinical programs – both synthetic peptides, and a bacterial polypeptide effective against Dengue and others RNA viruses:
